CMS to Finalize Drug Price Transparency Rule in 2025, Aiming to Lower Costs and Increase Accountability

Medicare drug spending will slow due to IRA price negotiations, CMS economists predict

Medicare spending on prescription drugs is expected to grow at a slower rate between 2028 and 2033 as a result of drug pricing provisions in the Inflation Reduction Act, a report by members of CMS' ...

CMS to Finalize Drug Price Transparency Rule in 2025, Aiming to Lower Costs and Increase Accountability

On June 24, U.S. Surgeon General Mehmet Oz announced that the Centers for Medicare & Medicaid Services (CMS) will finalize a rule this year requiring insurers to publicly report the net prices paid for prescription drugs. Originally proposed under the Trump administration and withdrawn in 2022, the rule has been revived as part of the Biden administration’s drug pricing reform efforts. If finalized, the rule would mandate both public and private…

CMS’ Strong Price Transparency Stance Leads to Citations for Nearly a Dozen Hospitals in 2025 Thus Far

Clinical laboratories should take a proactive approach to ensure compliance with current price transparency regulations Price transparency in healthcare continues to be a focus of the Centers for Medicare and Medicaid Services (CMS). As of this ebrief, the agency has cited nearly a dozen hospitals this year that failed to, wholly or in part, follow […] The post CMS’ Strong Price Transparency Stance Leads to Citations for Nearly a Dozen Hospitals…